DAWN Rheumatology - December 2013 Newsletter
4S Information Systems Ltd

December 2013 DAWN Rheumatology Software E-Newsletter

In this issue:

Season’s Greetings
All the staff at 4S DAWN Clinical Software would like to wish you a very happy holiday
and a great new year. We would also like to say a big Thank You to all our
DAWN customers – we really appreciate your business.

Support Desk Holiday Closures
Due to UK public holidays, the support desk will be closed on the 25th and 26th December and the 1st January. If you have any problems or issues on these dates, please email the support team at and a member of staff will be in contact with you the next working day.

Contacting Support and Ensuring Minimum Downtime for your Rheumatology System
If you require help from our support team, please contact them via email at where your email will be addressed as soon as possible by a member of the team. However, if your support issue is urgent, for example, if your system is down, please contact the team by phone on 015395 63091 so that your call can be dealt with as a priority.

• Regularly check the last backup date of your front screen tallies
• Remember, our support team is available at , or for urgent support issues, 015395 63091, 9.00am – 5.00pm Monday to Friday
• See for a recovery guide in the event of system issues outside UK office hours

Patient Demographics Interface – Best Practice
For those of you who have a patient demographics interface from your PAS system into DAWN RH, please remember to make any changes relating to the patient's contact details, i.e., address, within your PAS system rather than the DAWN RH system. Once a change has been made within the PAS system, this information will automatically get updated within DAWN AC.

If you amend details within the DAWN RH system first, then there is a chance that these could get overwritten with the old information from the PAS system. If you have any queries at all, please contact us at

Did you know.....

Experimental compound dramatically reduces joint inflammation
An experimental compound synthesized and developed by scientists from the Florida campus of The Scripps Research Institute (TSRI) has the capacity to significantly reduce joint inflammation in animal models of rheumatoid arthritis, an autoimmune disease that affects more than two million Americans. The study was published recently online ahead of print by the journal Arthritis & Rheumatism.

Personalising Biologic Treatment in RA Likely to Be Cost-Effective
Personalising adalimumab treatment for rheumatoid arthritis (RA) patients is likely to be cost-effective, new findings show. Using clinical response and drug levels (DLs) at six months to determine whether patients should continue taking the drug would result in substantial savings, Dr. Charlotte L. M. Krieckaert of the Jan van Breemen Research Institute in Amsterdam and colleagues found.

Biologicals Improve RA Function More Than Other DMARDs
Patients with RA who use biological disease-modifying anti-rheumatic drugs (bDMARDs) are more likely to have clinically relevant improvement in physical function compared with patients taking nonbiologic DMARDs (nbDMARDs), according to a meta-analysis reported in an article in the December issue of Rheumatology

Poor Public Awareness In Rheumatoid Arthritis Is Damaging Patients
New UK National Clinical Director for Musculoskeletal Conditions decries ‘scandalously’ low levels of public awareness of the disease.  Professor Peter Kay claims it is now the most
important issue standing in the way of improved health outcomes, he has today (at a Summit meeting in Parliament) publicly committed to take action on it and has called on the National Audit Office to instigate a fresh review.


Follow Us On Our LinkedIn Company Page
To keep up to date with all the latest news and developments, join our LinkedIn community and follow 4S DAWN Clinical Software.  

Copyright © 2013 4S Information Systems Ltd, All rights reserved.